200 related articles for article (PubMed ID: 22824230)
1. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
[TBL] [Abstract][Full Text] [Related]
2. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
3. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
McNicholas P; Wei Y; Whitcomb J; Greaves W; Black TA; Tremblay CL; Strizki JM
J Infect Dis; 2010 May; 201(10):1470-80. PubMed ID: 20373959
[TBL] [Abstract][Full Text] [Related]
4. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
5. Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1.
Parczewski M; Leszczyszyn-Pynka M; Urbanska A; Bander D; Boron-Kaczmarska A
J Med Virol; 2011 Nov; 83(11):1869-75. PubMed ID: 21915859
[TBL] [Abstract][Full Text] [Related]
6. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
Caseiro MM; Nelson M; Diaz RS; Gathe J; de Andrade Neto JL; Slim J; Solano A; Netto EM; Mak C; Shen J; Greaves W; Dunkle LM; Vilchez RA; Zeinecker J
J Infect; 2012 Oct; 65(4):326-35. PubMed ID: 22634184
[TBL] [Abstract][Full Text] [Related]
7. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
Wu E; Du Y; Gao X; Zhang J; Martin J; Mitreva M; Ratner L
J Virol; 2019 May; 93(9):. PubMed ID: 30787151
[TBL] [Abstract][Full Text] [Related]
8. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
[TBL] [Abstract][Full Text] [Related]
12. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
15. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
17. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
Visseaux B; Hurtado-Nedelec M; Charpentier C; Collin G; Storto A; Matheron S; Larrouy L; Damond F; Brun-Vézinet F; Descamps D;
J Infect Dis; 2012 Jan; 205(1):111-20. PubMed ID: 22140264
[TBL] [Abstract][Full Text] [Related]
19. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Seclén E; Garrido C; González Mdel M; González-Lahoz J; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1486-92. PubMed ID: 20427374
[TBL] [Abstract][Full Text] [Related]
20. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
